Health Care

Cardinal Health’s share price doubled in five years, outpacing the health‑services sector and boosting long‑term investors—learn why this growth matters.

Lonza bolsters market stability while expanding GMP‑compliant exosome manufacturing, partnering with Exogenus Therapeutics and Sartorius to accelerate clinical‑grade production.

Siemens Healthineers keeps buying shares, launches FDA‑approved D‑Dimer 2.0, and partners for lab‑diagnostics growth—what this means for investors.

AbbVie’s new bispecific antibody epcoritamab, combined with R‑CHOP, cuts progression or death in DLBCL by ~50% and could reshape lymphoma treatment and pricing in a $3‑$4 bn market.

Short‑sale disclosures reveal AQR Capital Management’s steady, long‑term bet against Sartorius AG, highlighting market sentiment amid a challenging biotech‑sector climate.

How Bayer’s new Ohio plant, restructuring, and digital health push shape its 2024 outlook—profitability, debt cuts, and value‑based reimbursement explained.

UnitedHealth’s board buys shares, boosting governance and aligning incentives with patient care and regulatory compliance.

Pfizer’s latest results show a steady 18.4% operating margin and 2.1% revenue growth, driven by value‑based reimbursement wins and global supply‑chain resilience.

Johnson & Johnson tops Q3 earnings, beating revenue and EPS estimates while boosting R&D in vaccines, oncology and AI diagnostics—insights on cost‑quality balance in healthcare.

German stocks inch up on Fresenius boost, but rising yields and EU policy shifts keep investors cautious; key sector insights and risks revealed.